British Journal of Cancer

Papers
(The H4-Index of British Journal of Cancer is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy590
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours462
Cancer health disparities in racial/ethnic minorities in the United States428
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets293
Deep learning in cancer pathology: a new generation of clinical biomarkers284
The lingering mysteries of metastatic recurrence in breast cancer261
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond231
Achieving clinical success with BET inhibitors as anti-cancer agents200
Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression173
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance149
Tumour treating fields therapy for glioblastoma: current advances and future directions133
Insights into the role of sialylation in cancer progression and metastasis126
How promising is phototherapy for cancer?124
Promises and challenges of adoptive T-cell therapies for solid tumours113
Treatment strategies for breast cancer brain metastases113
EMTome: a resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures112
Autophagy as a therapeutic target in pancreatic cancer106
The untapped potential of ascites in ovarian cancer research and treatment103
Cysteine metabolic circuitries: druggable targets in cancer99
Mutational drivers of cancer cell migration and invasion98
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials97
Radiomics and radiogenomics in gliomas: a contemporary update94
Emerging role of PTEN loss in evasion of the immune response to tumours91
Trends in cervical cancer incidence in sub-Saharan Africa89
The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO)82
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial78
Endocytosis: a pivotal pathway for regulating metastasis77
Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience76
The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 202076
Artificial intelligence in oncology: current applications and future perspectives73
Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)72
The gut microbiome: what the oncologist ought to know72
Metabolic reprogramming in prostate cancer70
Cell-free DNA analysis in current cancer clinical trials: a review70
Radiation-induced bystander and abscopal effects: important lessons from preclinical models68
Severity of COVID-19 in children with cancer: Report from the United Kingdom Paediatric Coronavirus Cancer Monitoring Project67
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study67
Artificial Intelligence-based methods in head and neck cancer diagnosis: an overview65
Cancer immunotherapy: it’s time to better predict patients’ response65
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma65
The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials64
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma63
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer63
Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration63
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours63
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours62
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours61
Towards decoding the coupled decision-making of metabolism and epithelial-to-mesenchymal transition in cancer61
Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer59
Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer59
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours58
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer57
Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy57
Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects55
Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence55
0.12413311004639